AMRI to acquire Aptuit businesses units for $60 million

US-based drug development and discovery company Aptuit has divested its aseptic clinical manufacturing site in Glasgow, UK, to US contract research organization Albany Molecular Research (Nasdaq: AMRI), said Aptuit’s chief executive Jonathan Goldman.

Aptuit has also entered into a definitive agreement with AMRI to acquire the West Lafayette, Indiana solid-state chemistry business for a total consideration of $60 million for both units, he added.

The acquisitions will expand AMRI's drug product development and aseptic clinical manufacturing capabilities. Servicing more than 250 customers a year, SSCI has an industry-leading reputation for solving difficult drug substance and formulated drug product challenges and is an expert in solid-state chemistry and analytical services. In addition, Aptuit's Glasgow facility will extend AMRI's capabilities platform to include sterile injectable drug product formulation and clinical stage manufacturing.